RT Journal Article
SR Electronic
T1 Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.27.20211433
DO 10.1101/2020.10.27.20211433
A1 Russell M. Petrak
A1 Nicholas W. Van Hise
A1 Nathan C. Skorodin
A1 Robert M. Fliegelman
A1 Vishnu Chundi
A1 Vishal Didwania
A1 Alice Han
A1 Brian P. Harting
A1 David W. Hines
YR 2020
UL http://medrxiv.org/content/early/2020/10/28/2020.10.27.20211433.abstract
AB Background SARS-CoV-2 is a novel coronavirus that has rapidly expanded to become a pandemic, resulting in millions of deaths worldwide. The cytokine storm is caused by the release of inflammatory agents and results in a physiologic disruption. Tocilizumab is an IL-6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with SARS-CoV-2.Methods This was a multi-center study of patients infected with SARS-CoV-2, admitted between 3/13/20 and 4/16/20, requiring mechanical ventilation. Parameters that were evaluated included age, sex, race, usage of steroids, inflammatory markers, and comorbidities. Early dosing was defined as a tocilizumab dose administered prior to or within one (1) day of intubation. Late dosing was defined as a dose administered greater than one (1) day after intubation. A control group that was treated only with standard of care, and without tocilizumab, was utilized for comparison (untreated).Findings We studied 118 patients who required mechanical ventilation. Eighty-one (81) received tocilizumab, compared to 37 who were untreated. Early tocilizumab therapy was associated with a statistically significant decrease in mortality as compared to patients who were untreated (p=0.003). Dosing tocilizumab late was associated with an increased mortality compared to the untreated group (p=0.006).Interpretation Early tocilizumab administration was associated with decreased mortality in critically ill SARS-Co-V-2 patients, but a potential detriment was suggested by dosing later in a patient’s course.Funding This work did not receive outside funding or sponsorship.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work did not receive outside funding or sponsorship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Western IRB 1019 39th Ave., SW Suite 120 Puyallup, WA 98374All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA deidentified dataset and the statistical analysis will be made available to the editor in chief or delegate for a period of 30 days from the time of submission for validation of results.